| Field | Specification |
|---|---|
| Mfr No | |
| Formulation | |
| Immunogen | Synthetic peptide taken within amino acid region 50-100 on human Thymic Stromal LymphoPoietin. |
| Product Type | |
| Storage | |
| UniProt # |
Product Overview
This synthetic TSLP Blocking Peptide corresponds to the immunogen sequence used to generate the paired anti-TSLP antibody (STJ505920). Pre-absorbing the antibody with this peptide before use demonstrates epitope-specific binding and confirms that observed signals in Western blot, IHC, or IF are attributable to the target protein, not antibody cross-reactivity.
Target & Specificity
| UniProt ID | Q969D9 |
|---|---|
| Immunogen | Synthetic peptide taken within amino acid region 50-100 on human Thymic Stromal LymphoPoietin. |
| Immunogen Region (aa) | 50-100 |
This blocking peptide is recommended for use in combination with TSLP antibody, STJ505920
Specifications
| Formulation | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
|---|---|
| Storage | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Validated Applications | Immunodepletion |
Pre-Absorption Specificity Protocol
- Dilute the anti-TSLP antibody to the recommended working concentration in assay buffer.
- Add the blocking peptide at a 5–10× molar excess relative to the antibody. For typical IHC conditions (2 μg/mL antibody): use 10–20 μg/mL blocking peptide.
- Incubate at room temperature for 1 hour (or at 4 °C overnight) with gentle mixing.
- Use the pre-absorbed mixture as the antibody solution in your standard WB/IHC/IF protocol, run in parallel with a non-blocked antibody control.
- Complete loss of signal in the pre-absorbed lane confirms epitope-specific binding. A non-specific irrelevant peptide should be included as a negative control.
Safety & Intended Use
Intended UseResearch Use Only (RUO)VendorSt John's Laboratory LtdCatalog No.STJ505712UniProtQ969D9
Pre-incubate the anti-TSLP antibody with this peptide at 5–10× molar excess (e.g., 5–10 μg peptide per 1–2 μg antibody) for 1–2 h at room temperature. Run parallel blots — one with antibody alone (positive), one with antibody + peptide. Loss of signal in the peptide-blocked lane confirms specificity.
Start at 5–10 μg/mL peptide alongside 1–2 μg/mL antibody. Increase to 20× molar excess if partial signal persists. For IHC, pre-incubation at 4 °C overnight improves blocking efficiency.
This peptide is designed to pair with antibody STJ505712. Immunogen region: Synthetic peptide taken within amino acid region 50-100 on human Thymic Stromal LymphoPoietin.. Using with a different antibody clone may not produce blocking results if epitopes differ.
Validated for Immunodepletion specificity controls. Performance in other applications (ELISA, IP) requires independent validation.
Store at-20°C for long term storage. Avoid freeze-thaw cycles.. Prepare single-use aliquots to avoid freeze-thaw; stable ≥12 months at −20 °C when lyophilized.
Looking for a custom format, bulk quantity, or specialized formulation? We offer flexible sourcing options. Contact us to discuss your specific requirements.
